City
Epaper

Stopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum Institute

By IANS | Updated: May 8, 2024 18:10 IST

New Delhi, May 8 As British-Swedish pharma giant AstraZeneca recalled its Covid-19 vaccine globally, Pune-based Serum Institute of ...

Open in App

New Delhi, May 8 As British-Swedish pharma giant AstraZeneca recalled its Covid-19 vaccine globally, Pune-based Serum Institute of India (SII) on Wednesday said it stopped the manufacturing and supply of additional doses of Covishield in December 2021.

AstraZeneca has voluntarily withdrawn the "marketing authorisation" of its Covid vaccine, sold as Covishield in India and Vaxzevria in Europe.

In a statement to IANS, an SII spokesperson said that with India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly.

"Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield," the spokesperson added.

The Serum Institute said that they fully understand the ongoing concerns and "it's crucial to emphasise our commitment to transparency and safety".

The company said that from the outset, "we have disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021".

Thrombotic Thrombocytopenic Syndrome (TTS) is a rare side effect that can cause people to have blood clots and a low blood platelet count, linked to at least 81 deaths in the UK as well as hundreds of serious injuries.

The SII stressed that despite the challenges faced during the global pandemic, the safety of the vaccine remains paramount.

"Regardless of whether it's AstraZeneca's Vaxzervria or our own Covishield, both vaccines have been instrumental in saving millions of lives worldwide.

"We commend the collaborative efforts of governments and ministries in facilitating a unified global response to the pandemic," added the Serum Institute.

Meanwhile, the British-Swedish multinational pharmaceutical is also being sued by more than 50 alleged victims and grieving relatives in a High Court case in the UK.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

MaharashtraPahalgam Terror Attack: 500 Tourists from Maharashtra Return Home in Two Days; State Government Arranges Special Flights (VIDEO)

Other SportsEx-Pak captain Rashid Latif calls Pahalgam attack 'heartbreaking incident'; calls for unity

NationalEx-Pak captain Rashid Latif calls Pahalgam attack 'heartbreaking incident'; calls for unity

NationalMaha CM directs completion of solar feeder project works by Sep 2026

AurangabadTeachers team get patent for ‘Imaging Device for Signature Recognition’

Health Realted Stories

HealthCentre extends financial aid to indigenous indoor air purification solution

HealthChildhood exposure to bacterial toxin can trigger Colorectal cancer among the young: Study

HealthIndia achieves breakthrough in gene therapy for haemophilia: Minister

LifestyleWalking Tips for Summer: Know the Best time to Walk to Avoid Heatstroke

HealthCentre launches campaign to achieve 100 pc Measles-Rubella immunisation coverage